||Ceritinib is a Kinase Inhibitor. The mechanism of action of Ceritinib is as a Tyrosine Kinase Inhibitor, and Cytochrome P450 3A Inhibitor, and Cytochrome P450 2C9 Inhibitor.
||Leupeptin hemisulfate is a reversible, competitive serine/cysteine protease inhibitor. It is an orally active, antioxidant and anti-inflammatory agent.
||Sivelestat is a potent and selective inhibitor of neutrophil elastase with IC50 of 44 nM.
||AA26-9 is an effective and broad-spectrum inhibitor of serine hydrolase.
||ML281 is a potent and selective STK33 inhibitor with IC50 of 14 nM.
||Amiloride hydrochloride is an effective sodium channel blocker of epithelial.
||SRPIN340, a serine/arginine-rich protein kinase (SRPK)-specific inhibitor, is potent for SRPK1 (IC50 = 0.89 uM).
||UK-371804 is an effective and specific uPA inhibitor. It was selected as a candidate for further preclinical evaluation for the treatment of chronic dermal ulcers.
||Phenylmethanesulfonyl fluoride (PMSF) is an enzyme inhibitor that inactivates IRC-50 arvin, subtilisin, and the fatty acid synthetase complex.
||SC-514 is a selective, orally active, ATP-competitive IKK-2 inhibitor (IC50=11.2±4.7 μM), obstructs NF-κB-dependent gene expression.
||Gabexate mesylate is a serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated intravascular coagulation (DIC), and as a regional anticoagulant for hemodialysis. The drug inhibits the hydrolytic effects of thrombin, plasmin, and kallikrein, but not of chymotry
||Nafamostat mesylate, a synthetic serine protease inhibitor,has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.
||Alvelestat is an orally bioavailable, selective and reversible inhibitor of human neutrophil elastase (NE), with potential anti-inflammatory activity.
||Diminazene is a trypanocidal agent.
||Aprotinin a broad-spectrum serine protease inhibitor, inhibiting the activity of a number of different esterases and proteases, including trypsin, chymotrypsin, kallikrein, plasmin, tissue plasminogen activator, and tissue and leukocytic proteinases.
||GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.